{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Tumor&page=15",
    "query": {
      "condition": "Germ Cell Tumor",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 5228,
    "total_pages": 523,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Tumor&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Tumor&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T04:41:23.241Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04650204",
      "title": "Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intractable Epilepsy",
        "Malignant Glioma",
        "Seizure Disorder",
        "WHO Grade 2 Glioma",
        "WHO Grade 3 Glioma"
      ],
      "interventions": [
        {
          "name": "Anticonvulsant Agent",
          "type": "DRUG"
        },
        {
          "name": "Perampanel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2020-12-04",
      "completion_date": "2023-04-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04650204"
    },
    {
      "nct_id": "NCT02709226",
      "title": "Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Astrocytoma, Grade IV",
        "Giant Cell Glioblastoma",
        "Glioblastoma Multiforme",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2016-06-15",
      "completion_date": "2023-07-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709226"
    },
    {
      "nct_id": "NCT03726515",
      "title": "CART-EGFRvIII + Pembrolizumab in GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "CART-EGFRvIII T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-03-11",
      "completion_date": "2021-02-27",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03726515"
    },
    {
      "nct_id": "NCT02142335",
      "title": "Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma of Skin Stage III",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Rituxan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Cancer Assocaties for Research & Excellence",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2014-03",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2014-05-20",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "Encinitas, California",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02142335"
    },
    {
      "nct_id": "NCT05061134",
      "title": "A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 194,
      "start_date": "2022-08-11",
      "completion_date": "2026-11-02",
      "has_results": true,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lutherville-Timonium",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05061134"
    },
    {
      "nct_id": "NCT02340884",
      "title": "A Pilot RCT of the PRISM Intervention for AYAs With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Acute Lymphoblastic Leukemia",
        "Lymphoma",
        "Sarcoma",
        "Acute Myelogenous Leukemia",
        "Brain Tumors",
        "Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Promoting Resilience In Stress Management (PRISM)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "13 Years to 25 Years"
      },
      "enrollment_count": 92,
      "start_date": "2015-01-30",
      "completion_date": "2021-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02340884"
    },
    {
      "nct_id": "NCT04264143",
      "title": "CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Pontine and Thalamic Gliomas",
        "Diffuse Midline Glioma"
      ],
      "interventions": [
        {
          "name": "Infusate with MTX110 and gadolinium",
          "type": "DRUG"
        },
        {
          "name": "Convection-Enhanced Delivery (CED)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Luca Szalontay",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 9,
      "start_date": "2020-03-10",
      "completion_date": "2023-11-22",
      "has_results": false,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04264143"
    },
    {
      "nct_id": "NCT00085306",
      "title": "Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Melanoma",
        "Recurrent Melanoma"
      ],
      "interventions": [
        {
          "name": "recombinant interferon beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2004-04",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-02",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085306"
    },
    {
      "nct_id": "NCT04596033",
      "title": "TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Cutaneous Squamous Cell Carcinoma",
        "Anal Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "GEN-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genocea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-11-11",
      "completion_date": "2022-06-27",
      "has_results": false,
      "last_update_posted_date": "2022-07-15",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04596033"
    },
    {
      "nct_id": "NCT03501134",
      "title": "Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "NovoTTF",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-08-08",
      "completion_date": "2021-06-03",
      "has_results": false,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-10-22T04:41:23.241Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03501134"
    }
  ]
}